209 results on '"Kroger, Nicolaus"'
Search Results
2. HEV infection in stem cell transplant recipients—retrospective study of EBMT Infectious Diseases Working Party
3. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
4. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
5. Trends in Allogeneic Transplantation for Favorable Risk Acute Myeloid Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT
6. Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Features in First Complete Remission As per the International Consensus Classification (ICC) 2022: A Study from the ALWP of the EBMT
7. Relapse Incidence Post Unrelated Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide (PTCy) in Patients with Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
8. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
9. Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis
10. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma
11. Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
12. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
13. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
14. Supplement 5 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
15. Supplement 6 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
16. Supplement 1 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
17. Supplement 2 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
18. Supplement 7 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
19. Supplement 3 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
20. Supplement 8 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
21. Supplement 4 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
22. Efficacy and Outcome of Allogeneic Transplantation in IgD and Nonsecretory Myeloma. A Report on Behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
23. Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party
24. Evaluation of Trends in Outcome over 2 Decades of Patients with Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplantation from Unrelated Donors: An ALWP/EBMT Analysis
25. HEV infection in stem cell transplant recipients—retrospective study of EBMT Infectious Diseases Working Party
26. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis
27. Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
28. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
29. Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
30. Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Poor Karnofsky Performance Status. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
31. Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) Using Treosulfan Based Compared to Standard Reduced-Intensity or Myeloablative Conditioning Regimens. a Report of the Chronic Malignancies Working Party of EBMT
32. Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Poor Karnofsky Performance Status Score. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
33. Allogenic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning in Patients With Refractory and Recurrent Multiple Myeloma: Long-Term Follow-Up
34. Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma – Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation
35. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
36. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors - a Retrospective Study By the EBMT Chronic Malignancies Working Party
37. 141 - Evaluation of Trends in Outcome over 2 Decades of Patients with Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplantation from Unrelated Donors: An ALWP/EBMT Analysis
38. In vivo T-cell depletion in patients with myelofibrosis transplanted from an HLA matched sibling donor: an EBMT study
39. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT
40. Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassified : A Retrospective Study by the Chronic Malignancies Working Party of the EBMT
41. The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT
42. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
43. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia
44. Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation
45. Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT
46. Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation
47. Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
48. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT
49. The EBMT Handbook
50. Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.